AI-designed drug candidate reverses biological age in clinical study

Insilico Drugs (“Insilico”), a clinical-stage firm centered on generative AI-driven drug discovery and growth, right now introduced the publication of a brand new examine performed in collaboration with a global crew of scientists from Harvard Medical Faculty, Stanford College, The Broad Institute, RWTH Aachen College, Peking College and Westlake College.

Utilizing longitudinal Olink proteomic information (CNCB OMIX accession: OMIX008341) collected throughout a Part IIa scientific trial of rentosertib, researchers evaluated organic age utilizing six internationally acknowledged, independently developed proteomic getting old clocks. All six fashions persistently indicated a discount in predicted organic age amongst sufferers handled with rentosertib. As well as, the Pressured Very important Capability (FVC), the important measure of lung perform declining with age, confirmed promising dose-dependent reversal in comparison with placebo aligning with the proteomic getting old clock age reversal.

Not too long ago printed in Nature Biotechnology, the examine represents the primary scientific analysis of a probably first-in-class drug candidate that includes each an AI-discovered goal with relevance to getting old and illness biology and an AI-designed molecule, reasonably than a repurposed generic drug corresponding to rapamycin or metformin. The findings additionally present a proof-of-concept framework for integrating getting old biomarkers into normal scientific trials to speed up the invention of geroprotective medicine and longevity therapeutics.

The outcomes shall be introduced by first creator Alex Zhavoronkov, founder and CEO of Insilico Drugs, on the Nature convention: Redefining Healthcare within the Age of AI, to be held at Sorbonne College in Paris on September 8, 2026.

From getting old biology to a scientific drug

Not like conventional geroscience research that depend on repurposed medicine like rapamycin or metformin, Insilico pursued a special method by incorporating getting old biology into its drug discovery technique from the outset.

Utilizing its AI-powered goal discovery platform, Insilico recognized TNIK as a novel goal implicated in getting old and fibrosis and carried out hallmarks of getting old evaluation the place TNIK scored extremely in 6 hallmarks. TNIK was subsequently prioritized as a dual-purpose goal related to each underlying getting old biology and idiopathic pulmonary fibrosis (IPF). Insilico’s generative chemistry platform, Chemistry42, was then deployed to design the small-molecule candidate rentosertib concentrating on TNIK. This system progressed from goal identification to preclinical candidate nomination in roughly 18 months, with the preclinical findings printed in Nature Biotechnology in 2024.

In June 2025, Insilico reported the outcomes of a Part IIa trial of Rentosertib for IPF (NCT05938920) in Nature Drugs. The trial met its major security endpoint and demonstrated a promising dose-dependent development in efficacy. One of many widespread efficacy consequence measures is Pressured Very important Capability (FVC), the important measure of lung perform. The standard age of onset of IPF is round 65 years. Apparently, in wholesome people older than 65, FVC declines as effectively usually on the fee of 20-50 mL/yr and may function a possible physiological biomarker of getting old. Within the earlier publication, it was revealed that within the 60-mg once-daily group, sufferers skilled a imply enchancment in pressured important capability (FVC) of +98.4 mL, in contrast with a imply decline of -20.3 mL within the placebo group (-62.3 excluding outlier).

Crucially, the trial protocol prospectively included longitudinal serum proteomic screening for exploratory biomarker analyses, which proved in step with the drug’s proposed anti-fibrotic and anti inflammatory exercise. All information collected from the trial have been subsequently deposited with the China Nationwide Middle for Bioinformation (CNCB), enabling the present investigation of organic getting old biomarkers.

Six totally different clocks level to robust organic age reversal measured by proteomics

Within the present examine, researchers evaluated serum proteome profiles from 42 trial contributors throughout 2,841 proteins. The crew utilized six independently developed proteomic getting old clocks, together with ProtAge, OrganAge (chronological and mortality variants), PAC, ipfP3GPT, and PAOPAC. Regardless of counting on various methodologies and coaching standards, all six clocks persistently exhibited a development towards reversed organic age amongst rentosertib-treated sufferers in comparison with placebo. The height impact is noticed at Week 4 in contributors receiving 30 mg BID with roughly 3-4 years reversal in organic age and as much as 6 years in a sure getting old clock.

Rentosertib decreases predicted organic age throughout varied regimens as measured by most getting old clocks, most importantly within the 30 mg BID group and in week 4.

Past modifications in organic age scores, the examine confirmed that rentosertib’s anti-aging results function partially unbiased of its respiratory advantages. Notably, the dose related to the best enchancment in lung perform differed from that producing the strongest age-reversal sign, suggesting that the drug’s geroprotective exercise was not merely a downstream consequence of illness enchancment.

This systemic influence was additional validated by means of comparisons with 55,319 UK Biobank profiles, which confirmed that rentosertib instantly reversed the everyday age-related protein-expression trajectories. Mechanistically, the drug acted as a senomorphic agent, suppressing key drivers of mobile senescence, together with EREG, ESM1, IGFBP4, ITGA2, MMP10, MMP13, and SPP1 whereas downregulating growth-factor signaling pathways related to accelerated getting old, together with RTK-PI3K and RAS-ERK, and modulating antioxidant and ldl cholesterol metabolisms.

A framework for the longer term

To assist reproducibility and additional analysis, all analysis information have been deposited at CNCB (accession OMIX008341), and the underlying pipeline code has been printed because the open-source Python library on GitHub.

Past these particular findings, the examine lays out a scalable blueprint for embedding geroscience endpoints into disease-focused drug growth. The analysis proposes a stepwise framework: amassing getting old and senescence biomarkers prospectively as exploratory endpoints in illness trials, and in the end pursuing biomarker qualification or composite scientific endpoints beneath the FDA Biomarker Qualification Program and FDA-NIH BEST framework. Such an method might floor geroprotective candidates years and even a long time sooner than the normal path of post-approval drug repurposing.

Insilico’s dual-purpose therapeutic technique can be proving its viability as a sustainable industrial mannequin. Not too long ago, Insilico reported whole income of roughly $106 million within the first half of 2026, a 287% year-over-year improve, and achieved its first worthwhile half-year since itemizing, with an adjusted web revenue exceeding $51 million. This milestone was pushed by a sequence of out-licensing, co-development, and R&D collaborations with international companions, together with Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia Therapeutics, CMS, and Tenacia. As of the newest practicable date, the full contract worth of transactions introduced by Insilico in 2026 reached roughly $7.3 billion, pushing the cumulative contract worth of its main collaborations since 2021 roughly $11 billion.

On the AI-driven R&D entrance, Insilico nominated 9 growth candidates inside 9 months of 2026 as of late August, setting a brand new firm document for annual pipeline productiveness and reaching eight scientific milestones throughout its proprietary and co-developed packages. Main this progress is rentosertib (ISM001-055), the world’s first drug candidate found and developed utilizing generative AI, which has superior to a Part III trial evaluating for idiopathic pulmonary fibrosis (IPF). As well as, Insilico Drugs launched a complete set of benchmarks that permit basis fashions to be evaluated in all duties wanted for drug discovery and launched state-of-the-art (SOTA) basis fashions outperforming different fashions and even inner instruments in benchmarks. Utilizing this new functionality Insilico hopes to broaden and speed up longevity drug discovery and growth each when it comes to scale, therapeutic modalities, and indications.

Business commentary

Six proteomic clocks from six unbiased teams, utilized to the identical 42 sufferers, all reported a youthful organic age within the handled arms. What convinces me isn’t the dimensions of the impact however the settlement, as a result of these fashions share neither their options nor their coaching information. This trial can’t but separate slower getting old from a handled lung, and the authors say so plainly. The experiment in wholesome volunteers is the one I wish to see subsequent.”

Michael Levitt, PhD, 2013 Nobel Prize laureate in Chemistry

” Insilico Drugs was constructed with one function – to develop a reputable and sustainable enterprise mannequin for the event of frontier deep studying know-how and its utility to sensible getting old analysis and drug discovery with the aim of creating utilizing AI and sensible discovery and growth of longevity therapeutics. This primary program demonstrates the primary proof of idea for the novel dual-purpose therapeutic concentrating on getting old however proposed towards the age-related illness found in document time making exploratory growth in a number of indications commercially viable.

Right this moment, the vast majority of Insilico’s 40+ drug packages have twin function concentrating on getting old and illness in a broad vary of therapeutic areas. By pursuing a reputable biotechnology enterprise mannequin, the corporate reached profitability and established the longevity board, which is uncommon for the publicly-traded frontier biotechnology firm. I’m additionally glad that the drug carries the identify of the true hero of the AI drug discovery revolution, our co-CEO, Dr. Ren.

The social and financial alternative for medicine reversing organic age is huge – trillions of {dollars} and billions of life years. Should you add simply 3 further years to everybody’s lifespan, that interprets into roughly 25 billion life years on the worldwide scale – at present life expectancy, that’s roughly 340 million human lifetimes. Extra lifetimes than humanity misplaced in all of the wars ever fought. Should you handle so as to add 3 years to everybody’s life, the drug ought to have the ability to considerably prolong the wholesome portion of life as effectively translating into trillions of {dollars} in productiveness and financial savings” , mentioned Alex Zhavoronkov, PhD, founder and co-CEO of Insilico Drugs.

” On this examine, we evaluated scientific trial information to check the blood proteomic profiles of pulmonary fibrosis sufferers handled with Rentosertib versus placebo” , mentioned Ludger Goeminne, Analysis Fellow in Drugs at Harvard Medical Faculty, and co-author of the paper. “Utilizing six proteomic getting old clocks together with fashions our crew printed in Cell Metabolism, we noticed vital reductions in predicted organic age throughout a number of organ-specific clocks, and additional pathway evaluation confirmed that Rentosertib’s organic influence extends far past merely decreasing fibrosis.”

“Because the developer of PAOPAC (Proteome-Conscious Organ Proxy Getting older Clock), I’m thrilled to see our device utilized to the evaluation of the Part IIa scientific trial for rentosertib. Dr. Zhavoronkov and his colleagues are the primary to systematically consider a novel drug candidate utilizing a number of proteomic getting old clocks inside a single scientific trial cohort. The methodologies underlying these clocks vary from conventional machine studying (OrganAge, PAOPAC, PAC) to deep studying (ProtAge, ipfP3GPT), with coaching targets encompassing each chronological age (ProtAge, OrganAgechrono, ipfP3GPT, PAOPAC) and mortality danger (PAC, OrganAgemortality). Throughout the board, these clocks persistently predicted a discount in organic age inside the rentosertib remedy group. This cross-model consistency demonstrates that rentosertib’s impact on aging-related proteomic alerts isn’t a model-specific artifact, however reasonably a extremely sturdy organic phenomenon.” mentioned Professor Jing-Dong Jackie Han, Peking-Tsinghua Middle for Life Sciences, Academy for Superior Interdisciplinary Research, Middle for Quantitative Biology (CQB), China. ” Moreover, this examine establishes a comparatively complete workflow for the standardized utility of getting old clocks in scientific trials, overlaying cohort institution, omics profiling, multi-clock parallel evaluation, consequence cross-validation, and mechanistic interpretation. It additionally introduces an revolutionary sensible method to scientific trial design: evaluating getting old biomarkers in parallel throughout trials concentrating on particular indications, significantly age-related ailments. This technique holds nice promise for accelerating the invention and validation of longevity interventions.

Lastly, my congratulations on the breakthrough achieved with rentosertib – an revolutionary drug found in China and clinically evaluated primarily in Chinese language affected person cohorts. As a home Chinese language analysis crew behind the event of getting old clocks, we look ahead to witnessing extra industry-academia-research collaborations driving future scientific trials in getting old interventions.”